MOMitsuo Oshimura

Mitsuo Oshimura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mitsuo Oshimura has a total of 219 co-authors. Here are the top co-authors by number of shared publications:

  • Makiko Meguro

    Division of Molecular and Cell Genetics, Department of Molecular and Cellular Biology, School of Life Sciences, Faculty of Medicine, Tottori University, Tottori, Japan

    8 shared publications
  • Motonobu Katoh

    Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science, Tottori University, 86 Nishicho, Yonago, Tottori 683–8503, Japan

    8 shared publications
  • Yasuhiro Kazuki

    Tottori University

    8 shared publications
  • Kohzoh Mitsuya

    Biofunctional Science, Tohoku University Biomedical Engineering Research Organization (TUBERO), Sendai, Japan

    7 shared publications
  • Hidetoshi Hoshiya

    Department of Biomedical Science , Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Nishi-cho , Yonago, Tottori , Japan

    6 shared publications
  • Hiroyuki Kugoh

    Tottori University

    6 shared publications

Latest Publications

  • Open Access

    Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model

    by Yasuhiro Kazuki, Masaharu Akita, Kaoru Kobayashi, Mitsuhiko Osaki, Daisuke Satoh, Ryo Ohta, Satoshi Abe, Shoko Takehara, Kanako Kazuki, Hiroshi Yamazaki, et al.

    Thalidomide is a teratogen in humans but not in rodents. It causes multiple birth defects including malformations of limbs, ears, and other organs. However, the species-specific mechanism of thalidomide teratogenicity is not completely understood. Reproduction of the human teratogenicity of thalidomide in rodents has previously failed because of the lack of a model reflecting human drug metabolism. In addition, because the maternal metabolic effect cannot be eliminated, the migration of unchanged thalidomide to embryos is suppressed, and the metabolic activation is insufficient to develop teratogenicity. Previously, we generated transchromosomic mice containing a human cytochrome P450 (CYP) 3A cluster in which the endogenous mouseCyp3agenes were deleted. Here, we determined whether human CYP3A or mouse Cyp3a enzyme expression was related to the species difference in a whole embryo culture system using humanized CYP3A mouse embryos. Thalidomide-treated embryos with the humanCYP3Agene cluster showed limb abnormalities, and human CYP3A was expressed in the placenta, suggesting that human CYP3A in the placenta may contribute to the teratogenicity of thalidomide. These data suggest that the humanized CYP3A mouse is a useful model to predict embryonic toxicity in humans.


  • Open Access

    Mouse embryonic stem cells with a multi-integrase mouse artificial chromosome for transchromosomic mouse generation

    by Yuki Yoshimura, Kazuomi Nakamura, Takeshi Endo, Naoyo Kajitani, Kanako Kazuki, Yasuhiro Kazuki, Hiroyuki Kugoh, Mitsuo Oshimura, Tetsuya Ohbayashi

    The mouse artificial chromosome (MAC) has several advantages as a gene delivery vector, including stable episomal maintenance of the exogenous genetic material and the ability to carry large and/or multiple gene inserts including their regulatory elements. Previously, a MAC containing multi-integration site (MI-MAC) was generated to facilitate transfer of multiple genes into desired cells. To generate transchromosomic (Tc) mice containing a MI-MAC with genes of interest, the desired genes were inserted into MI-MAC in CHO cells, and then the MI-MAC was transferred to mouse embryonic stem (mES) cells via microcell-mediated chromosome transfer (MMCT). However, the efficiency of MMCT from CHO to mES cells is very low (−6). In this study, we constructed mES cell lines containing a MI-MAC vector to directly insert a gene of interest into the MI-MAC in mES cells via a simple transfection method for Tc mouse generation. The recombination rate of the GFP gene at each attachment site (FRT, PhiC31attP, R4attP, TP901-1attP and Bxb1attP) on MI-MAC was greater than 50 % in MI-MAC mES cells. Chimeric mice with high coat colour chimerism were generated from the MI-MAC mES cell lines and germline transmission from the chimera was observed. As an example for the generation of Tc mice with a desired gene by the MI-MAC mES approach, a Tc mouse strain ubiquitously expressing Emerald luciferase was efficiently established. Thus, the findings suggest that this new Tc strategy employing mES cells and a MI-MAC vector is efficient and useful for animal transgenesis.


  • Open Access

    Down syndrome-associated haematopoiesis abnormalities created by chromosome transfer and genome editing technologies

    by Yasuhiro Kazuki, Yuwna Yakura, Satoshi Abe, Mitsuhiko Osaki, Naoyo Kajitani, Kanako Kazuki, Shoko Takehara, Kazuhisa Honma, Hirofumi Suemori, Satoshi Yamazaki, et al.

    Infants with Down syndrome (DS) are at a high risk of developing transient abnormal myelopoiesis (TAM). A GATA1 mutation leading to the production of N-terminally truncated GATA1 (GATA1s) in early megakaryocyte/erythroid progenitors is linked to the onset of TAM and cooperated with the effect of trisomy 21 (Ts21). To gain insights into the underlying mechanisms of the progression to TAM in DS patients, we generated human pluripotent stem cells harbouring Ts21 and/or GATA1s by combining microcell-mediated chromosome transfer and genome editing technologies. In vitro haematopoietic differentiation assays showed that the GATA1s mutation blocked erythropoiesis irrespective of an extra chromosome 21, while Ts21 and the GATA1s mutation independently perturbed megakaryopoiesis and the combination of Ts21 and the GATA1s mutation synergistically contributed to an aberrant accumulation of skewed megakaryocytes. Thus, the DS model cells generated by these two technologies are useful in assessing how GATA1s mutation is involved in the onset of TAM in patients with DS.


  • An induced pluripotent stem cell-mediated and integration-free factor VIII expression system

    by Yuwna Yakura, Chie Ishihara, Hajime Kurosaki, Yasuhiro Kazuki, Norio Komatsu, Yoshiaki Okada, Takefumi Doi, Hiroyuki Takeya, Mitsuo Oshimura


    • 1 December 2011
      • Vol. 69  (12) , 2142-7

    [Toward gene and cell therapy using human artificial chromosome].

    by Yasuhiro Kazuki, Mitsuo Oshimura

    Human artificial chromosomes (HACs) exhibit several potential characteristics desired for an ideal gene delivery vector, including stable episomal maintenance and the capacity to carry large genomic loci with their regulatory elements, thus allowing the physiological regulation of the introduced gene. Stem cells, including hematopoietic stem cells, bone marrow-derived MSCs and iPS cells, can potentially avoid immune rejection due to their being obtained from the patient's own tissues. Recently, we succeeded the complete correction of a genetic deficiency in iPS cells derived from a human Duchenne muscular dystrophy patient using the HAC technology. Therefore, the combination of patient specific stem cells and HAC containing defective genes potentially represents a powerful tool for gene and cell therapies.

  • Open Access

    Human Artificial Chromosomes for Gene Delivery and the Development of Animal Models

    by Yasuhiro Kazuki, Mitsuo Oshimura


  • Open Access

    Refined human artificial chromosome vectors for gene therapy and animal transgenesis

    by Y Kazuki, H Hoshiya, M Takiguchi, S Abe, Y Iida, M Osaki, M Katoh, M Hiratsuka, Y Shirayoshi, K Hiramatsu, et al.

    Human artificial chromosomes (HACs) have several advantages as gene therapy vectors, including stable episomal maintenance, and the ability to carry large gene inserts. We previously developed HAC vectors from the normal human chromosomes using a chromosome engineering technique. However, endogenous genes were remained in these HACs, limiting their therapeutic applications. In this study, we refined a HAC vector without endogenous genes from human chromosome 21 in homologous recombination-proficient chicken DT40 cells. The HAC was physically characterized using a transformation-associated recombination (TAR) cloning strategy followed by sequencing of TAR-bacterial artificial chromosome clones. No endogenous genes were remained in the HAC. We demonstrated that any desired gene can be cloned into the HAC using the Cre-loxP system in Chinese hamster ovary cells, or a homologous recombination system in DT40 cells. The HAC can be efficiently transferred to other type of cells including mouse ES cells via microcell-mediated chromosome transfer. The transferred HAC was stably maintained in vitro and in vivo. Furthermore, tumor cells containing a HAC carrying the suicide gene, herpes simplex virus thymidine kinase (HSV-TK), were selectively killed by ganciclovir in vitro and in vivo. Thus, this novel HAC vector may be useful not only for gene and cell therapy, but also for animal transgenesis.


    • 1 September 2010
      • Vol. 82  (9) , 846-52

    [Advantages and applications of human artificial chromosome vector].

    by Shigeyuki Yamaguchi, Tetsuya Ohbayashi, Yasuhiro Kazuki, Mitsuo Oshimura

  • Open Access

    Human Artificial Chromosome with a Conditional Centromere for Gene Delivery and Gene Expression

    by Yuichi Iida, Jung-Hyun Kim, Yasuhiro Kazuki, Hidetoshi Hoshiya, Masato Takiguchi, Masahiro Hayashi, Indri Erliandri, Hee-Sheung Lee, Alex Samoshkin, Hiroshi Masumoto, et al.

    Human artificial chromosomes (HACs), which carry a fully functional centromere and are maintained as a single-copy episome, are not associated with random mutagenesis and offer greater control over expression of ectopic genes on the HAC. Recently, we generated a HAC with a conditional centromere, which includes the tetracycline operator (tet-O) sequence embedded in the alphoid DNA array. This conditional centromere can be inactivated, loss of the alphoidtet-O (tet-O HAC) by expression of tet-repressor fusion proteins. In this report, we describe adaptation of the tet-O HAC vector for gene delivery and gene expression in human cells. A loxP cassette was inserted into the tet-O HAC by homologous recombination in chicken DT40 cells following a microcell-mediated chromosome transfer (MMCT). The tet-O HAC with the loxP cassette was then transferred into Chinese hamster ovary cells, and EGFP transgene was efficiently and accurately incorporated into the tet-O HAC vector. The EGFP transgene was stably expressed in human cells after transfer via MMCT. Because the transgenes inserted on the tet-O HAC can be eliminated from cells by HAC loss due to centromere inactivation, this HAC vector system provides important novel features and has potential applications for gene expression studies and gene therapy.


  • Open Access

    Complete Genetic Correction of iPS Cells From Duchenne Muscular Dystrophy

    by Yasuhiro Kazuki, Masaharu Hiratsuka, Masato Takiguchi, Mitsuhiko Osaki, Naoyo Kajitani, Hidetoshi Hoshiya, Kei Hiramatsu, Toko Yoshino, Kanako Kazuki, Chie Ishihara, et al.